Document is current
Any future updates will be listed below
-
Authors
Scheller, Leo https://orcid.org/0000-0003-2490-4015
Giordano Attianese, Greta Maria Paola
Castellanos-Rueda, Rocío https://orcid.org/0000-0002-9674-4172
Di Roberto, Raphaël B. https://orcid.org/0000-0003-0976-5395
Barden, Markus
Triboulet, Melanie https://orcid.org/0009-0001-6408-7366
Hafezi, Morteza
Ash, Sarah
Shui, Sailan
Cribioli, Elisabetta
Reichenbach, Patrick
Maillard, Jimmy
Marchand, Anthony https://orcid.org/0000-0003-2864-0408
Georgeon, Sandrine https://orcid.org/0000-0002-8158-4508
Wolf, Benita
Abken, Hinrich https://orcid.org/0000-0002-4302-3240
Reddy, Sai https://orcid.org/0000-0002-9177-0857
Correia, Bruno E. https://orcid.org/0000-0002-7377-8636
Irving, Melita https://orcid.org/0000-0002-6849-7194
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 21 January 2026
First Online: 19 February 2026
Competing interests
: S.T.R. holds shares of Alloy Therapeutics and Engimmune Therapeutics. S.T.R. is on the scientific advisory board of Alloy Therapeutics and Engimmune Therapeutics. M.I., B.E.C., G.G.A., L.S., and colleagues have provisional intellectual property rights for the DROP mechanism.
